Literature DB >> 21827355

Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease.

Anders B Mathiasen1, Marina J Harutyunyan, Erik Jørgensen, Steffen Helqvist, Rasmus Ripa, Jens P Gøtze, Julia S Johansen, Jens Kastrup.   

Abstract

BACKGROUND: YKL-40 is a glycoprotein secreted by macrophages and neutrophils in tissues with inflammation. Plasma YKL-40 is increased in patients with coronary artery disease (CAD) and associated with cardiovascular and all-cause mortality. Furthermore, plasma YKL-40 seems related to the number of diseased main vessels in patients with stable CAD. The aim was to further study the relation between YKL-40 and stenosis degree, stenosis type and actual ischemia in stable CAD patients.
METHODS: Plasma YKL-40 and hsCRP levels were determined from 206 consecutive patients with stable angina pectoris admitted for coronary angiography. Plasma YKL-40 in 245 healthy subjects was used for comparison. In addition to one to three vessel stenosis scores, two new scores for evaluating coronary angiographies were established for discriminating between focal and diffuse CAD and the extent of myocardial ischemia.
RESULTS: YKL-40 levels in CAD patients (median: 52 μg/L and quartiles: 37-85 μg/L) were significantly increased (p < 0.001) compared to the healthy controls. In univariate analyses plasma YKL-40 was significantly associated with ischemic myocardium score, age, hypertension, peripheral vascular disease and serum creatinine levels. In multivariate analyses YKL-40 was related to hsCRP, peripheral artery disease, hypertension, and statin treatment.
CONCLUSIONS: Plasma YKL-40 was increased in patients with CAD compared to controls. YKL-40 was related to the ischemic myocardium, but not to degree of CAD using different scoring systems. Therefore, YKL-40 is not related to the extent of CAD, but to some other pathophysiological mechanisms of importance for the prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827355     DOI: 10.3109/00365513.2011.586470

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  12 in total

1.  Diagnostic Value of Serum YKL-40 Level for Coronary Artery Disease: A Meta-Analysis.

Authors:  Chun-Li Song; Hong-Ying Diao; Jiang-Hua Wang; Yong-fei Shi; Yang Lu; Guan Wang; Zi-Yuan Guo; Yang-Xue Li; Jian-Gen Liu; Jin-Peng Wang; Ji-Chang Zhang; Zhuo Zhao; Yi-Hang Liu; Ying Li; Dan Cai; Qian Li
Journal:  J Clin Lab Anal       Date:  2016-01       Impact factor: 2.352

2.  Surgical Acute Volume-Overload Impacts Early on Myocardium - An Experimental Study.

Authors:  Christa Huuskonen; Mari Hämäläinen; Robin Bolkart; Tatu Soininen; Veera Kähönen; Timo Paavonen; Eeva Moilanen; Ari A Mennander
Journal:  Acta Cardiol Sin       Date:  2017-11       Impact factor: 2.672

3.  Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus.

Authors:  Hyun Min Kim; Byung-Wan Lee; Young-Mi Song; Won Jin Kim; Hyuk-Jae Chang; Dong-Hoon Choi; Hee Tae Yu; Eunseok Kang; Bong Soo Cha; Hyun Chul Lee
Journal:  Cardiovasc Diabetol       Date:  2012-07-18       Impact factor: 9.951

4.  The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test.

Authors:  Naja Dam Mygind; Anna Axelsson; Martin H Ruwald; Morten Dalsgaard; Rolf Steffensen; Kasper Iversen; Julia S Johansen; Jens Kastrup
Journal:  Cardiovasc Endocrinol       Date:  2016-01-04

5.  Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40.

Authors:  Hui Zhang; Wenping Zhou; Chang Cao; Wenjing Zhang; Gangqiong Liu; Jinying Zhang
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

6.  Relationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population.

Authors:  Eva Aguilera; Enric Serra-Planas; M Luisa Granada; Silvia Pellitero; Jordi L Reverter; Núria Alonso; Berta Soldevila; Dídac Mauricio; Manel Puig-Domingo
Journal:  Cardiovasc Diabetol       Date:  2015-09-18       Impact factor: 9.951

7.  Increased expression of chitinase 3-like 1 in aorta of patients with atherosclerosis and suppression of atherosclerosis in apolipoprotein E-knockout mice by chitinase 3-like 1 gene silencing.

Authors:  Zushun Gong; Shanshan Xing; Fei Zheng; Qichong Xing
Journal:  Mediators Inflamm       Date:  2014-03-04       Impact factor: 4.711

8.  Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome.

Authors:  Mehmet Kadri Akboğa; Rıdvan Yalçın; Asife Şahinarslan; Canan Yılmaz Demirtaş; Hatice Paşaoğlu; Adnan Abacı
Journal:  Anatol J Cardiol       Date:  2016-06-29       Impact factor: 1.596

Review 9.  Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?

Authors:  Alexander Tenenbaum; Enrique Z Fisman
Journal:  Cardiovasc Diabetol       Date:  2017-07-19       Impact factor: 9.951

10.  Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.

Authors:  Jakob Schroder; Janus Christian Jakobsen; Per Winkel; Jørgen Hilden; Gorm Boje Jensen; Ahmad Sajadieh; Anders Larsson; Johan Ärnlöv; Marina Harutyunyan; Julia S Johansen; Erik Kjøller; Christian Gluud; Jens Kastrup
Journal:  J Am Heart Assoc       Date:  2020-03-02       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.